HealthTree Radio for AML: Margaret Kasner, MD, Thomas Jefferson University
Update: 2022-02-07
Description
About 30% of acute myeloid leukemia patients have developed a mutation in the FLT3 gene. Up until recently, this specific mutation usually resulted in poor treatment outcomes. Today, we have several drugs designed to directly target this mutation and even more progress is occurring with newer drugs and various treatment combinations in clinical trials.
Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this episode is definitely for you.
Thank you to our episode sponsor, Jazz Pharmaceuticals.
Dr. Kasner, an AML expert from the Sidney Kimmel Cancer Center at Thomas Jefferson University, will summarize key developments and clinical trials currently underway for FLT3 positive AML. If you have a FLT3 mutation, this episode is definitely for you.
Thank you to our episode sponsor, Jazz Pharmaceuticals.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
